Customer publications – B-355
← Return to all publications
O. V. Timmermand, J. Elgqvist, K. A. Beattie, A. Örbom, E. Larsson, S. E. Eriksson, D. L. J. Thorek, B. J. Beattie, T. A. Tran, D. Ulmert, S. E. Strand. Preclinical efficacy of hK2 targeted [¹⁷⁷Lu]hu11B6 for prostate cancer theranostics
Theranostics, vol. 9, 2019, pp. 2129-2142
A. Y. Liu, A. D. Kanan, T. P. Radon, S. Shah, M. E. Weeks, J. M. Foster, J. K. Sosabowski, L. Dumartin, T. Crnogorac-Jurcevic. AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting
Oncotarget, vol. 10, 2019, pp. 4276-4289
E. Deshayes, R. Ladjohounlou, P. Le Fur, A. Pichard, C. Lozza, V. Boudousq, S. Sevestre, M. Jarlier, R. Kashani, J. Koch, J. Sosabowski, J. Foster, N. Chouin, F. Bruchertseifer, A. Morgenstern, P. O. Kotzki, I. Navarro-Teulon, J. P. Pouget. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
J Nucl Med, vol. 59, 2018, pp. 1234-1242
M. E. Autenrieth, C. Seidl, F. Bruchertseifer, T. Horn, F. Kurtz, B. Feuerecker, C. D'Alessandria, C. Pfob, S. Nekolla, C. Apostolidis, S. Mirzadeh, J. E. Gschwend, M. Schwaiger, K. Scheidhauer, A. Morgenstern. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
Eur J Nucl Med Mol Imaging, vol. 45, 2018, pp. 1364-1371